GlassScriptPhysician profile
Karen M Baxley
NPI 1336146380
$4,488.01
in general payments reported to CMS, 2019-2025
25 companies · $15.38 in 2025
The $15.38 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $575 · 2022: $1,195 · 2023: $1,687 · 2024: $1,017 · 2025: $15.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $906.65 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $889.94 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $657.90 | 2022-2024 | Xarelto, Spravato |
| Amgen INC. | $480.92 | 2021-2024 | Prolia, Evenity, Repatha |
| Ibsa Pharma INC. | $250.00 | 2023-2024 | Tirosint |
| Glaxosmithkline, LLC. | $224.28 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $153.75 | 2023-2024 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $120.84 | 2024 | Quviviq |
| Abbott Laboratories | $118.04 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $117.45 | 2021-2023 | |
| Esperion Therapeutics, INC. | $111.22 | 2021 | |
| Alexion Pharmaceuticals, INC. | $102.72 | 2023 | Ultomiris |
| Alkermes, INC. | $100.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.93 | 2022 | |
| Daiichi Sankyo INC. | $38.27 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.16 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $24.13 | 2022 | |
| Vivus LLC | $19.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.80 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $16.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.38 | 2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $14.96 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.28 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.75 | 2022 | |
| Kerecis Limited | $9.24 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Baxley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.